Shin Nippon Biomedical Laboratories (FRA:YB3) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:YB3 Shin Nippon Biomedical Laboratories Ltd FRA:YB3
74 GF Score
Price €6.00
GF Value €9.47
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Shin Nippon Biomedical Laboratories's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:YB3 vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shin Nippon Biomedical Laboratories Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Margin of Safety % (DCF Earnings Based) falls into.


FRA:YB3
74GF Score
Shin Nippon Biomedical Laboratories Ltd FRA:YB3
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shin Nippon Biomedical Laboratories (FRA:YB3) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of €6.00 is trading 36.6% below its estimated GF Value™ of €9.47.

Key valuation signals for FRA:YB3:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €9.47 vs. price of €6.00 (36.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:YB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for FRA:YB3

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€9.47
GF Value